Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 1
1(33.3%)
3Total
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01785563Not ApplicableCompleted

Nasal Noninvasive NAVA in the Very Low Birth Weight Infant

Role: lead

NCT00296231Phase 1Completed

Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study

Role: lead

NCT01232725Not ApplicableCompleted

Donor Human Milk and Neurodevelopmental Outcomes in Very Low Birthweight (VLBW) Infants

Role: lead

All 3 trials loaded